News
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
On the same day that United Airlines forecast stability, Abbott Labs warned investors to expect a $200 million hit.
Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...
Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Abbott Laboratories ( NYSE: ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback